세계의 동형접합 가족성 고콜레스테롤혈증 시장 : 산업 규모, 점유율, 동향, 기회 및 예측 - 약제 클래스별, 투여 경로별, 기술별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Homozygous Familial Hypercholesterolemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Technology, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1703275
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 184 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
동형접합 가족성 고콜레스테롤혈증 세계 시장은 2024년에 8,267만 달러로 평가되었습니다. 2030년에는 1억397만 달러에 달할 것으로 예상되며, 3.87%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
이 시장은 광범위한 제약 및 헬스케어 분야의 중요한 부문으로, 동형접합 가족성 고콜레스테롤혈증으로 알려진 희귀하고 심각한 유전성 질환에 대한 대응에 초점을 맞추었습니다. 이 유전질환의 관리 및 치료를 위한 치료 솔루션의 개발, 생산, 유통을 전문으로 하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
8,267만 달러
시장 규모 : 2030년
1억 397만 달러
CAGR : 2025-2030년
3.87%
급성장 부문
스타틴
최대 시장
북미
HoFH는 상염색체 열성 유전질환으로 혈중 저밀도 지단백 콜레스테롤(LDL-C) 농도가 비정상적으로 높은 상염색체 열성 유전질환으로 조기에 심각한 심혈관계 합병증을 유발하며, HoFH에 걸리면 젊은 나이부터 심장마비 및 기타 심혈관계 질환의 위험이 현저하게 높아져 평생에 걸친 전문 의료서비스가 필요하게 됩니다. 필요하게 됩니다.
생명공학, 유전학, 약리학의 비약적인 발전으로 인해 최근 몇 년 동안 HoFH 시장이 크게 성장하고 있습니다. 제약업계의 선두주자들은 이 쇠약해진 질환을 더 잘 관리하고 치료할 수 있는 단클론항체, 유전자 치료, RNA 기반 치료 등 혁신적인 치료법을 발견하기 위해 연구개발에 적극적으로 투자하고 있습니다. 이러한 새로운 치료법은 LDL-C 수치를 획기적으로 낮추고 환자의 삶의 질을 개선할 수 있을 것으로 기대되고 있습니다.
주요 시장 성장 촉진요인
주요 시장 과제
주요 시장 동향
이러한 발전은 HoFH 시장의 역동적인 특성을 강조하며, 치료법 및 의료 서비스 제공의 혁신으로 인해 큰 성장 잠재력을 가지고 있습니다.
Global Homozygous Familial Hypercholesterolemia Market was valued at USD 82.67 million in 2024 and is projected to reach USD 103.97 million by 2030, growing at a compound annual growth rate (CAGR) of 3.87%. This market is a vital segment within the broader pharmaceutical and healthcare sectors, focused on addressing the rare and severe genetic disorder known as Homozygous Familial Hypercholesterolemia. It is dedicated to the development, production, and distribution of therapeutic solutions aimed at managing and treating this genetic condition.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 82.67 Million
Market Size 2030
USD 103.97 Million
CAGR 2025-2030
3.87%
Fastest Growing Segment
Statins
Largest Market
North America
HoFH is an autosomal recessive disorder marked by abnormally high levels of low-density lipoprotein cholesterol (LDL-C) in the bloodstream, which leads to early and severe cardiovascular complications. Individuals affected by HoFH face significantly increased risks of heart attacks and other cardiovascular issues from a young age, necessitating lifelong, specialized medical care.
The HoFH market has seen significant growth in recent years, driven by breakthroughs in biotechnology, genetics, and pharmacology. Pharmaceutical leaders are actively investing in research and development to discover innovative therapies, such as monoclonal antibodies, gene therapies, and RNA-based treatments, to better manage and potentially cure this debilitating condition. These novel therapies show promise in dramatically lowering LDL-C levels and improving patients' quality of life.
Key Market Drivers
Advancements in Biotechnology and Genetics: Breakthroughs in biotechnology and genetics have been pivotal in propelling the growth of the HoFH market. Monoclonal antibodies like evinacumab (Evkeeza) have been instrumental in this progress. Approved by the U.S. FDA in February 2021, evinacumab inhibits angiopoietin-like 3 (ANGPTL3), a protein that obstructs lipid breakdown. By targeting ANGPTL3, evinacumab significantly reduces LDL-C levels in HoFH patients, decreasing the risk of cardiovascular complications. Clinical trials have confirmed its transformative potential in treating HoFH.
Key Market Challenges
High Development Costs: A major challenge facing the HoFH market is the high development costs associated with creating therapies for this ultra-rare genetic disorder. HoFH affects roughly 1 in a million individuals globally, resulting in a small and geographically dispersed patient population. This scarcity complicates clinical trial recruitment and raises costs related to patient participation and data collection. Additionally, the complex nature of HoFH requires extensive research and multi-phase clinical trials, further driving up development costs.
Key Market Trends
Telemedicine and Remote Monitoring: Telemedicine and remote monitoring technologies have become transformative in the management of HoFH, addressing the challenges posed by geographic and specialist access limitations. Telemedicine enables patients to consult with specialized healthcare providers remotely, ensuring timely and consistent care. Through telehealth platforms, healthcare professionals can monitor patient progress, suggest lifestyle changes, and adjust treatments as needed, reducing the need for in-person visits.
Furthermore, remote monitoring technologies, including wearable devices and mobile applications, allow patients to track their cholesterol levels, medication adherence, and overall health. This continuous monitoring provides healthcare providers with real-time data, allowing for prompt interventions and minimizing the risk of cardiovascular events.
These advancements highlight the dynamic nature of the HoFH market, with significant potential for growth driven by innovation in therapeutic treatments and healthcare delivery.
Key Market Players
AstraZeneca PLC
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Accord Healthcare
Changzhou Pharmaceutical Factory
Regeneron Pharmaceuticals, Inc.
Amryt Pharma plc
Amgen Inc.
Organon Global Inc.
CMP Pharma
Report Scope:
In this report, the Global Homozygous Familial Hypercholesterolemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Homozygous Familial Hypercholesterolemia Market, By Drug Class:
Statins
Cholesterol Absorption Inhibitors
PCSK9 Inhibitors
MTP Inhibitors
ANGPTL3 Inhibitors
Homozygous Familial Hypercholesterolemia Market, By Route of Administration:
Oral
Parenteral
Nasal
Homozygous Familial Hypercholesterolemia Market, By Technology:
CRISPR-Cas9
RNA Interference
Nanoparticle-Based Therapies
Homozygous Familial Hypercholesterolemia Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Homozygous Familial Hypercholesterolemia Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Homozygous Familial Hypercholesterolemia Market.
Available Customizations:
Global Homozygous Familial Hypercholesterolemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Homozygous Familial Hypercholesterolemia Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Drug Class (Statins, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, MTP Inhibitors, ANGPTL3 Inhibitors)
4.2.2. By Route of Administration (Oral, Parenteral, Nasal)
4.2.3. By Technology (CRISPR-Cas9, RNA Interference, Nanoparticle-Based Therapies)
4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.5. By Region
4.2.6. By Company (2024)
4.3. Market Map
4.3.1. By Drug Class
4.3.2. By Route of Administration
4.3.3. By Technology
4.3.4. By Distribution Channel
4.3.5. By Region
5. Asia Pacific Homozygous Familial Hypercholesterolemia Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class
5.2.2. By Route of Administration
5.2.3. By Technology
5.2.4. By Distribution Channel
5.2.5. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Homozygous Familial Hypercholesterolemia Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Drug Class
5.3.1.2.2. By Route of Administration
5.3.1.2.3. By Technology
5.3.1.2.4. By Distribution Channel
5.3.2. India Homozygous Familial Hypercholesterolemia Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Drug Class
5.3.2.2.2. By Route of Administration
5.3.2.2.3. By Technology
5.3.2.2.4. By Distribution Channel
5.3.3. Australia Homozygous Familial Hypercholesterolemia Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Drug Class
5.3.3.2.2. By Route of Administration
5.3.3.2.3. By Technology
5.3.3.2.4. By Distribution Channel
5.3.4. Japan Homozygous Familial Hypercholesterolemia Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Drug Class
5.3.4.2.2. By Route of Administration
5.3.4.2.3. By Technology
5.3.4.2.4. By Distribution Channel
5.3.5. South Korea Homozygous Familial Hypercholesterolemia Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Drug Class
5.3.5.2.2. By Route of Administration
5.3.5.2.3. By Technology
5.3.5.2.4. By Distribution Channel
6. Europe Homozygous Familial Hypercholesterolemia Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Route of Administration
6.2.3. By Technology
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. Europe: Country Analysis
6.3.1. France Homozygous Familial Hypercholesterolemia Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Technology
6.3.1.2.4. By Distribution Channel
6.3.2. Germany Homozygous Familial Hypercholesterolemia Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Technology
6.3.2.2.4. By Distribution Channel
6.3.3. Spain Homozygous Familial Hypercholesterolemia Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Technology
6.3.3.2.4. By Distribution Channel
6.3.4. Italy Homozygous Familial Hypercholesterolemia Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Drug Class
6.3.4.2.2. By Route of Administration
6.3.4.2.3. By Technology
6.3.4.2.4. By Distribution Channel
6.3.5. United Kingdom Homozygous Familial Hypercholesterolemia Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Drug Class
6.3.5.2.2. By Route of Administration
6.3.5.2.3. By Technology
6.3.5.2.4. By Distribution Channel
7. North America Homozygous Familial Hypercholesterolemia Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration
7.2.2. Drug Class
7.2.3. By Distribution Channel
7.2.4. By Technology
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Homozygous Familial Hypercholesterolemia Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Technology
7.3.1.2.4. By Distribution Channel
7.3.2. Mexico Homozygous Familial Hypercholesterolemia Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Technology
7.3.2.2.4. By Distribution Channel
7.3.3. Canada Homozygous Familial Hypercholesterolemia Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Technology
7.3.3.2.4. By Distribution Channel
8. South America Homozygous Familial Hypercholesterolemia Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Homozygous Familial Hypercholesterolemia Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Technology
8.3.1.2.4. By Distribution Channel
8.3.2. Argentina Homozygous Familial Hypercholesterolemia Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Technology
8.3.2.2.4. By Distribution Channel
8.3.3. Colombia Homozygous Familial Hypercholesterolemia Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Technology
8.3.3.2.4. By Distribution Channel
9. Middle East and Africa Homozygous Familial Hypercholesterolemia Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Drug Type
9.2.3. By Technology
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Homozygous Familial Hypercholesterolemia Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Technology
9.3.1.2.4. By Distribution Channel
9.3.2. Saudi Arabia Homozygous Familial Hypercholesterolemia Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Drug Type
9.3.2.2.3. By Technology
9.3.2.2.4. By Distribution Channel
9.3.3. UAE Homozygous Familial Hypercholesterolemia Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Technology
9.3.3.2.4. By Distribution Channel
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Homozygous Familial Hypercholesterolemia Market: SWOT Analysis
